KOSELUGO 7.5 mg, granules in a capsule to be opened 60 capsules
Active ingredients: HYDROGÉNOSULFATE DE SÉLUMÉTINIB, SÉLUMÉTINIB
Commercialized according to BDPMDispensing in France: Prescription only
Granules in capsules60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KOSELUGO 7,5 mg, granulés en gélule à ouvrir
- Pharmaceutical form
- granulés en gélule
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 gélule(s)
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 23 Jun 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
67016392CIP73033295CIP133400930332955Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SÉLUMÉTINIBgranulés | 7,5 mg · une gélule | FT |
| HYDROGÉNOSULFATE DE SÉLUMÉTINIBgranulés | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.